Portola Pharma Bulks Up

Portola Pharmaceuticals Inc., a South San Francisco-based drug company focused on thrombosis and related cardiovascular diseases, has raised $70 million in Series C funding. New backers include Brookside Capital, AllianceBernstein, Teachers' Private Capital, Goldman Sachs, T. Rowe Price, IBTM and CIDC. Returnees included Abingworth Management, Alta Partners, Advanced Technology Ventures, Frazier Healthcare, MPM Capital, Prospect Ventures and Sutter Hill Ventures. Portola now has raised around $160 million in total VC funding. www.portola.com